natgillin/translations-raw huggingface dataset:
Mimpara 30 mg film-coated tablets Mimpara 60 mg film-coated tablets Mimpara 90 mg film-coated tablets Cinacalcet
Mimpara 30 mg filmsko obložene tablete Mimpara 60 mg filmsko obložene tablete Mimpara 90 mg filmsko obložene tablete cinakalcet
It may harm them, even if their symptoms are the same as yours.
Njim bi lahko celo škodovalo, čeprav imajo simptome bolezni, enake vašim.
What Mimpara is and what it is used for 2.
Kaj je zdravilo Mimpara in za kaj ga uporabljamo 2.
Before you take Mimpara 3.
Kaj morate vedeti, preden boste vzeli zdravilo Mimpara 3.
How to take Mimpara 4.
Kako jemati zdravilo Mimpara 4.
Possible side effects 5 How to store Mimpara 6.
Možni neželeni učinki 5 Shranjevanje zdravila Mimpara 6.
WHAT MIMPARA IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO MIMPARA IN ZA KAJ GA UPORABLJAMO
Mimpara works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorous in your body.
Mimpara deluje tako, da v telesu uravnava koncentracijo paratiroidnega hormona (PTH), kalcija in fosforja.
It is used to treat problems with organs called parathyroid glands.
Uporabljamo jo za zdravljenje težav z obščitnicami (obščitničnimi žlezami).
Mimpara is used: • to treat secondary hyperparathyroidism in patients with kidney disease on dialysis. • to reduce high levels of calcium in the blood (hypercalcaemia) in patients with parathyroid cancer. • to reduce high levels of calcium in the blood (hypercalcaemia) in patients with primary hyperparathyroidism who still have high calcium levels after removal of the parathyroid gland or when removal of the gland is not possible.
Mimparo uporabljamo: • za zdravljenje sekundarnega hiperparatiroidizma pri bolnikih z boleznijo ledvic na dializi. • za zmanjšanje hiperkalciemije (zvišane koncentracije kalcija v krvi) pri bolnikih z rakom obščitnic. • za zmanjšanje zvišane koncentracije kalcija v krvi (hiperkalciemije) pri bolnikih s primarnim hipertiroidizmom, ki imajo koncentracijo kalcija zvišano tudi po odstranitvi obščitnic, ali če odstranitev teh žlez ni mogoča.
In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroids.
Pri primarnem in sekundarnem hiperparatiroidizmu nastaja v obščitnicah preveč PTH.
This can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.
Posledice so lahko bolečine v kosteh in zlomi kosti, težave s srcem in ožiljem, ledvični kamni, duševna bolezen in koma.
BEFORE YOU TAKE MIMPARA
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO MIMPARA
Do not take Mimpara:
Ne jemljite zdravila Mimpara:
• DO NOT take Mimpara if you are allergic (hypersensitive) to cinacalcet or any of the other ingredients of Mimpara.
• NE JEMLJITE ZDRAVILA Mimpara, če ste alergični na (preobčutljivi za) cinakalcet ali katerokoli sestavino zdravila Mimpara.
58 Take special care with Mimpara:
58 Bodite posebno pozorni pri jemanju zdravila Mimpara:
Before you start taking Mimpara, tell your doctor if you have or have ever had
Preden začnete uporabljati Mimparo, morate zdravniku povedati, če imate ali ste kdaj imeli
• seizures (fits or convulsions).
• napade krčev (konvulzije).
The risk of having seizures is higher if you have had them before; • liver problems.
Tveganje za pojav konvulzij je večje, če ste jih imeli že kdaj prej. • težave z jetri.
During treatment with Mimpara, tell your doctor: • if you start or stop smoking, as this may affect the way Mimpara works.
Med zdravljenjem z Mimparo morate zdravniku povedati: • če začnete ali nehate kaditi, kajti to lahko vpliva na delovanje Mimpare.
Please tell your doctor if you are taking the following medicines.
Zdravniku morate povedati, če jemljete naslednja zdravila:
These can affect how Mimpara works: • medicines used to treat skin and fungal infections (ketoconazole, itraconazole, voriconazole); • antibiotics used to treat bacterial infections (telithromycin, rifampicin); • medicine used to treat HIV infection and AIDS (ritonavir).
Na delovanje Mimpare lahko vplivajo naslednja zdravila: • zdravila za zdravljenje kožnih in glivičnih okužb (ketokonazol, itrakonazol, vorikonazol), • antibiotiki za zdravljenje bakterijskih okužb (telitromicin, rifampicin), • zdravilo za zdravljenje okužbe s HIV in aidsa (ritonavir).
Mimpara may affect how the following work: • medicines used to treat depression (amitriptyline, desipramine, nortriptyline, clomipramine and fluvoxamine); • medicines used to treat changes in heart rate (flecainide and propafenone); • medicine used to treat high blood pressure (metoprolol when given in heart failure); • antibiotic used to treat bacterial infections (ciprofloxacin).
Mimpara lahko vpliva na delovanje naslednjih zdravil: • zdravil za zdravljenje depresije (amitriptilin, dezipramin, nortriptilin, klomipramin in fluvoksamin), • zdravil za zdravljenje motenj srčnega ritma (flekainid in propafenon), • zdravil za zdravljenje visokega krvnega tlaka (metoprolol, kadar je uporabljen za srčno popuščanje), • antibiotika za zdravljenje bakterijskih okužb (ciprofloksacin).
Taking Mimpara with food and drink
Jemanje zdravila Mimpara skupaj s hrano in pijačo:
Mimpara should be taken with or shortly after food.
Mimparo morate vzeti s hrano ali kmalu po jedi.
Always tell your doctor if you are pregnant or planning to become pregnant.
Zdravniku morate vedno povedati, če ste noseči ali nameravate zanositi.
Mimpara has not been tested in pregnant women.
Mimpara ni preizkušena pri nosečnicah.
In case of pregnancy, your doctor may decide to modify your treatment, as Mimpara might harm the foetus.
Če zanosite, se bo zdravnik morda odločil, da vam zdravljenje prilagodi; Mimpara namreč lahko škoduje plodu.
It is not known whether Mimpara is excreted in human milk.
Ni znano, ali se Mimpara izloča v materinem mleku.
Your doctor will discuss with if you should discontinue either breast-feeding or treatment with Mimpara.
Vaš zdravnik se bo pogovoril z vami o prenehanju bodisi dojenja bodisi zdravljenja z Mimparo.
Mimpara should not affect your ability to drive and use machines.
Mimpara ne bi smela vplivati na vašo sposobnost vožnje in upravljanja s stroji.
However, it is advisable to wait and see how you feel after taking Mimpara and before driving or operating machinery.
Vendar je priporočljivo, da po uporabi Mimpare počakate in ugotovite, kako se počutite, preden upravljate vozila ali stroje.
If you have an intolerance to some sugars
Če imate intoleranco za nekatere sladkorje
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Če vam je zdravnik povedal, da imate intoleranco za nekater sladkorje, se z njim posvetujte, preden vzamete to zdravilo.
HOW TO TAKE MIMPARA
KAKO JEMATI ZDRAVILO MIMPARA
Children under the age of 18 must not take Mimpara.
Mimpare ne smejo jemati otroci, mlajši od 18 let.
Always take Mimpara exactly as your doctor has told you.
Natančno upoštevajte zdravnikova navodila.
You should check with your doctor or pharmacist if you are unsure.
Če ste v dvomih, se posvetujte z zdravnikom ali farmacevtom.
Your doctor will tell you how much Mimpara you must take.
Zdravnik vam bo povedal, koliko Mimpare morate uporabiti.
Mimpara must be taken orally, with or shortly after food.
Mimparo morate zaužiti, in sicer s hrano ali kmalu po jedi.
Your doctor will take regular blood samples during treatment to monitor your progress and will adjust your dose if necessary.
Zdravnik vam bo med zdravljenjem redno jemal kri, da bo nadziral potek; če bo treba, vam bo prilagodil odmerek.
The usual starting dose for Mimpara is 30 mg (one tablet) once per day.
Običajni začetni odmerek Mimpare je 30 mg (ena tableta) enkrat na dan.
The usual starting dose for Mimpara is 30 mg (one tablet) twice per day.
Običajni začetni odmerek Mimpare je 30 mg (ena tableta) dvakrat na dan.
If you take more Mimpara than you should you must contact your doctor immediately.
Če vzamete več Mimpare, kot bi je smeli, se morate takoj posvetovati s svojim zdravnikom.
Do not take a double dose to make up for forgotten doses.
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjega.
If you have forgotten a dose of Mimpara, you should take your next dose as normal.
Če ste pozabili odmerek Mimpare, vzemite naslednjega kot ponavadi.
Like all medicines, Mimpara can have side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Mimpara neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Very common side effects (seen in more than 1 in 10 people taking Mimpara): • nausea and vomiting, these side effects are normally quite mild and do not last for long.
Zelo pogosti neželeni učinki( pojavijo se pri več kot 1 od 10 oseb, ki uporabljajo Mimparo): • slabost v želodcu in bruhanje; ta učinka sta ponavadi zelo blaga in ne trajata dolgo.
Common side effects (seen in more than 1 in 100 people taking Mimpara): • dizziness • numbness or tingling sensation (paraesthesia) • loss of appetite (anorexia) • muscle pain (myalgia) • weakness (asthenia) • rash • reduced testosterone levels
Pogosti neželeni učinki (pojavijo se pri več kot 1 od 100 oseb, ki uporabljajo Mimparo): • omotica, • omrtvelost ali mravljinčenje (parestezije), • izguba apetita (anoreksija), • bolečina v mišici (mialgija), • šibkost (astenija), • izpuščaj, • znižanje koncentracije testosterona.
Uncommon side effects (seen in more than 1 in 1000 people taking Mimpara): • seizures • indigestion (dyspepsia) • diarrhoea • allergic reaction (hypersensitivity)
Občasni neželeni učinki (pojavijo se pri več kot 1 od 1. 000 oseb, ki uporabljajo Mimparo): • napadi krčev (konvulzije), • težave z želodcem( dispepsija),
60 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures you should tell you doctor immediately.
Zdravniku morate nemudoma povedati, če se vam začnejo pojavljati omrtvelost ali mravljinčenje okrog ust, bolečine ali krči v mišicah, ali napadi krčev (konvulzije).
After taking Mimpara a very small number of patients with heart failure had worsening of their condition.
Zelo majhnemu številu bolnikov s srčnim popuščanjemse je stanje po uporabi Mimpare poslabšalo.
Low blood pressure (hypotension) has also been seen in a very small number of these patients.
Pri zelo majhnem številu teh bolnikov so zabeležili tudi nizek krvni tlak (hipotenzijo).
As so few cases have been seen it is not known whether they are due to Mimpara, or not.
Ker je bilo teh primerov tako malo, ni mogoče reči, ali so bili posledica Mimpare ali ne.
HOW TO STORE MIMPARA
SHRANJEVANJE ZDRAVILA MIMPARA
Do not use Mimpara after the expiry date which is stated on the outer carton and on the blister.
Zdravila Mimpara ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na zunanji ovojnini in na pretisnem omotu.
(or) Do not use Mimpara after the expiry date which is stated on the outer carton and on the bottle.
Zdravila Mimpara ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na zunanji ovojnini in na vsebniku za tablete.
The other ingredients are: • Pre-gelatinised maize starch • Microcrystalline cellulose • Povidone • Crospovidone • Magnesium stearate • Colloidal anhydrous silica
Pomožne snovi so: • predgelirani koruzni škrob, • mikrokristalna celuloza, • povidon, • krospovidon, • magnezijev stearat, • brezvodni koloidni silicijev dioksid.
The tablets are coated with: • Carnauba wax • Opadry green (containing lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD & C Blue (E132), iron oxide yellow (E172)) • Opadry clear (containing hypromellose, macrogol)
Tablete so obložene s: • karnauba voskom, • Opadry zeleno (vsebuje monohidrat laktoze, hipromelozo, titanov dioksid (E171), gliceroltriacetat, indigotin (E132) in rumeni železov oksid (E172)), • Opadry prozorno (vsebuje hipromelozo in makrogol).
The printing ink contains: shellac glaze, iron oxide black (E172).
Črnilo za tiskanje vsebuje: glazuro šelaka in črni železov oksid (E172).
What Mimpara looks like and contents of the pack
61 Izgled zdravila Mimpara in vsebina pakiranja
Mimpara is a light green film-coated tablet.
Mimpara je svetlozelena, filmsko obložena tableta.
They are oval-shaped and have “ 30”, “ 60” or “ 90” printed on one side and “ Amgen” on the other side.
Tablete so ovalne oblike in imajo na eni strani oznako "30", "60" ali "90", na drugi strani pa napis "Amgen".
Mimpara is available in blisters of 30 mg, 60 mg or 90 mg film-coated tablets.
Mimpara je na voljo v pretisnih omotih v 30- mg, 60- mg ali 90- mg filmsko obloženih tabletah.
Each blister pack contains either 14, 28 or 84 tablets in a carton.
Vsak pretisni omot vsebuje 14, 28 ali 84 tablet v škatlici.
61 Mimpara is available in bottles of 30 mg, 60 mg or 90 mg film-coated tablets, inside a carton.
Mimpara je na voljo v vsebnikih za tablete (30- mg, 60- mg ali 90- mg filmsko obložene tablete) v škatlici.
Each bottle holds 30 tablets.
Vsak vsebnik za tablete vsebuje 30 tablet.
Mirapexin is a medicine containing the active substance pramipexole base.
Mirapexin je zdravilo, ki vsebuje zdravilno učinkovino pramipeksolijev hidroksid.
0.088, 0.7 and 1.1 mg; oval:
0, 088, 0, 7 in 1, 1 mg; ovalnih:
0.18 and 0.35 mg).
0, 18 in 0, 35 mg).
Mirapexin is used to treat the symptoms of the following diseases: • Parkinson’ s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Zdravilo Mirapexin se uporablja za zdravljenje simptomov naslednjih bolezni: • Parkinsonove bolezni, tj. napredujoče okvare možganov, ki povzroča tresavico, upočasnjeno izvajanje gibov in okorelost mišic.
Mirapexin can be used either on its own or in combination with levodopa (another medicine for Parkinson’ s disease), at any stage of disease including the later stages when levodopa starts becoming less effective; • moderate to severe restless legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night.
Zdravilo Mirapexin se lahko uporablja samostojno ali v kombinaciji z levodopo (drugim zdravilom za zdravljenje Parkinsonove bolezni) v katerem koli stadiju bolezni, vključno s kasnejšimi stadiji, ko začne učinkovitost levodope upadati; • zmernega do hudega sindroma nemirnih nog, tj. motnje, pri kateri ima bolnik nenadzorovano potrebo po premikanju okončin, da bi se znebil neprijetnih, bolečih ali nenavadnih občutkov v telesu, navadno ponoči.
Mirapexin tablets should be swallowed with water, with or without food.
Tablete Mirapexin se pogoltnejo z vodo, hrano ali brez nje.
For Parkinson’ s disease, the starting dose is 0.088 mg three times per day.
Pri Parkinsonovi bolezni je začetni odmerek 0, 088 mg trikrat dnevno.
The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated.
Odmerek je treba povečevati vsakih pet do sedem dni, dokler se ne vzpostavi nadzor nad simptomi, ne da bi se pojavili nevzdržni neželeni učinki.
The maximum daily dose is 1.1 mg three times per day.
Največji dnevni odmerek je 1, 1 mg trikrat dnevno.
Mirapexin must be given less frequently in patients who have problems with their kidneys.
Zdravilo Mirapexin je treba bolnikom, ki imajo težave z ledvicami, dajati manj pogosto.
If treatment is stopped for any reason, the dose should be decreased gradually.
Če je treba zdravljenje iz katerega koli razloga ustaviti, je treba odmerek zmanjševati postopoma.
For restless legs syndrome, Mirapexin should be taken once a day, two to three hours before going to bed.
Pri sindromu nemirnih nog je treba zdravilo Mirapexin jemati enkrat dnevno, dve do tri ure pred spanjem.
The recommended starting dose is 0.088 mg, but, if needed, this can be increased every four to seven days to reduce symptoms further, to a maximum of 0.54 mg.
Priporočeni začetni odmerek je 0, 088 mg, vendar ga je mogoče po potrebi, z namenom nadaljnjega zmanjšanja simptomov, povečati vsake štiri do sedem dni do najvišjega odmerka 0, 54 mg.
The patient’ s response and the need for further treatment should be evaluated after three months.
Po treh mesecih je treba oceniti bolnikov odziv in potrebo po nadaljnjem zdravljenju.
The active substance in Mirapexin, pramipexole, is a dopamine agonist, which imitates the action of dopamine.
Zdravilna učinkovina zdravila Mirapexin, pramipeksol, je agonist dopamina, ki posnema delovanje dopamina.
Dopamine is a messenger substance in the parts of the brain that control movement and co-ordination.
Dopamin je prenašalec v delu možganov, ki nadzira gibanje in koordinacijo.
In patients with Parkinson’ s disease, the cells that produce dopamine begin to die and 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Pri bolnikih s 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
The patients then lose their ability to control their movements reliably.
Parkinsonovo boleznijo pričnejo celice, ki proizvajajo dopamin, odmirati, zato se količina dopamina v možganih zmanjša.
Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’ s disease, such as shaking, stiffness and slowness of movement.
Pramipeksol stimulira možgane enako kot dopamin, tako da lahko bolniki nadzirajo svoje gibe ter imajo manj znakov in simptomov Parkinsonove bolezni, kot so tresavica, okorelost in upočasnjenost gibov.
The way pramipexole works in restless legs syndrome is not fully understood.
Način učinkovanja pramipeksola pri sindromu nemirnih nog ni v celoti razjasnjen.
The syndrome is thought to be caused by problems in the way dopamine works in the brain, which may be corrected by pramipexole.
Sindrom naj bi nastal zaradi težav pri delovanju dopamina v možganih, kar pa lahko uravnamo s pramipeksolom.
In Parkinson’ s disease, Mirapexin has been studied in five main studies involving 1,546 patients.
Pri Parkinsonovi bolezni so zdravilo Mirapexin proučevali v petih glavnih študijah, v katere je bilo vključenih 1546 bolnikov.
Four studies compared the effects of Mirapexin with those of placebo (a dummy treatment): one study in 360 patients with advanced disease who were already taking levodopa that was starting to become less effective, and three studies in a total of 886 patients with early disease who were not receiving levodopa.
V štirih študijah so primerjali učinke zdravila Mirapexin z učinki placeba (zdravila brez zdravilne učinkovine): v eni študiji s 360 bolniki z napredovalo boleznijo, ki so že jemali levodopo, katere učinkovitost je začela upadati, in v treh študijah s skupno 886 bolniki z boleznijo v zgodnjem stadiju, ki niso prejemali levodope.
The main measure of effectiveness was the change in scores before and after treatment obtained with a standard questionnaire used to measure the severity of Parkinson’ s disease.
Glavno merilo učinkovitosti je bila sprememba rezultatov pred zdravljenjem in po njem, pridobljenih s standardnim vprašalnikom, ki se uporablja za merjenje resnosti Parkinsonove bolezni.
The fifth study compared the effects of Mirapexin with those of levodopa in 300 patients with early disease.
V peti študiji so primerjali učinke zdravila Mirapexin z učinki levodope pri 300 bolnikih z boleznijo v zgodnjem stadiju.
Its main measure of effectiveness was the proportion of patients who had movement symptoms.
Glavno merilo učinkovitosti je bil delež bolnikov z motoričnimi simptomi.
In all studies, Mirapexin doses were increased gradually over six to ten weeks before being maintained at a stable dose.
V vseh študijah so odmerke zdravila Mirapexin postopoma povečevali šest do deset tednov, nato pa vzdrževali stalni odmerek.
Mirapexin has also been studied in two main studies of patients with restless legs syndrome.
Zdravilo Mirapexin so proučevali tudi v dveh glavnih študijah z bolniki s sindromom nemirnih nog.
The first included 344 patients and compared the effects of three doses of Mirapexin with those of placebo.
V prvi študiji, v katero je bilo vključenih 344 bolnikov, so primerjali učinke treh odmerkov zdravila Mirapexin z učinki placeba.
The main measure of effectiveness was the improvement in symptoms between the start and end of the study, measured using two standard scales.
Glavno merilo učinkovitosti je bilo izboljšanje simptomov med začetkom in koncem študije, ki so jih merili z dvema standardnima lestvicama.
The other study included 150 patients who took Mirapexin for six months, and compared the effects of remaining on Mirapexin or switching to placebo.
V drugo študijo je bilo vključenih 150 bolnikov, ki so zdravilo Mirapexin jemali šest mesecev; v njej so primerjali učinke nadaljevanja jemanja zdravila Mirapexin z učinki prehoda na placebo.
In the study of patients with advanced Parkinson’ s disease, patients taking Mirapexin had larger improvements after 24 weeks of steady-dose treatment than those taking placebo.
V študiji z bolniki z napredovalo Parkinsonovo boleznijo je bilo pri bolnikih, ki so jemali zdravilo Mirapexin, po 24 tednih zdravljenja s stalnim odmerkom doseženo večje izboljšanje kot pri bolnikih, ki so jemali placebo.
Similar results were seen in the first three studies of early Parkinson’ s disease, with greater improvements after four or 24 weeks.
Podobni rezultati so bili opaženi v prvih treh študijah Parkinsonove bolezni v zgodnjem stadiju, kjer je prišlo do večjih izboljšanj po štirih ali 24 tednih.
28% of the patients taking Mirapexin had symptoms (42 out of 151) compared with 51% of the patients taking levodopa (76 out of 150).
Po 21 mesecih je imelo motorične simptome manjše število bolnikov, ki so jemali zdravilo Mirapexin, kot bolnikov, ki so jemali levodopo: simptome je imelo 28% bolnikov, ki so jemali zdravilo Mirapexin (42 od 151), v primerjavi z 51% bolnikov, ki so jemali levodopo (76 od 150).
In the first study of restless legs syndrome, symptom scores fell by between 12.8 and 14.0 points after 12 weeks in patients taking Mirapexin, compared with a fall of 9.3 points in the patients taking placebo.
V prvi študiji sindroma nemirnih nog so se pri bolnikih, ki so jemali zdravilo Mirapexin, ocene simptomov po 12 tednih izboljšale za 12, 8 do 14, 0 točke v primerjavi z zmanjšanjem za 9, 3 točke pri bolnikih, ki so jemali placebo.
Scores were around 23 points at the start of the study.
Na začetku študije so bile ocene simptomov približno 23 točk.
The difference between placebo and Mirapexin was greatest after four weeks before getting smaller.
Razlika med učinki placeba in zdravila Mirapexin je bila največja po štirih tednih, nato pa se je zmanjšala.
More patients taking Mirapexin also had an improvement in symptoms.
Poleg tega je doseglo izboljšanje simptomov več tistih bolnikov, ki so jemali zdravilo Mirapexin.
The results of the other study were insufficient to prove the long- term effectiveness of Mirapexin.
Rezultati druge študije niso zadostovali, da bi dokazali dolgoročno učinkovitost zdravila Mirapexin.
The most common side effect with Mirapexin (seen in more than 1 patient in 10) is nausea (feeling sick).
Najpogostejši neželeni učinek zdravila Mirapexin (opažen pri več kot 1 bolniku izmed 10) je navzeja (občutek slabosti).
In patients with Parkinson’ s disease, the other side effects seen in more than 1 patient in 10 are dizziness, dyskinesia (difficulty controlling movement), somnolence (sleepiness) and hypotension (low blood pressure).
Pri bolnikih s Parkinsonovo boleznijo so drugi neželeni učinki, opaženi pri več kot 1 bolniku izmed 10) omotica, diskinezija (otežen nadzor nad gibanjem), somnolenca (zaspanost) in hipotenzija (nizek krvni tlak).
For the full list of all side effects reported with Mirapexin, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Mirapexin, glejte navodilo za uporabo.